![Thomas Smart](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Smart
Vorstandsvorsitzender bei Actym Therapeutics, Inc.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Laura Hix Glickman | M | - |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | - |
Kenneth Kelley | M | 64 |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | - |
Martin Driscoll | M | 65 |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
James Neal | M | 68 |
XOMA (US) LLC
![]() XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA. | - |
Julie Cherrington | M | 66 |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | 2 Jahre |
Jesal Shah | M | - |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
Alexis Ji | M | - |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | 4 Jahre |
Kanad D. Das | M | - |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | - |
Sheriese Rush | F | - |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | - |
James D. Huang | M | - |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | - |
Susan Sobolov | M | - |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
Nathalie Dubois Stringfellow | M | - |
XOMA (US) LLC
![]() XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA. | - |
Monica Zhou | M | - |
RIGImmune, Inc.
![]() RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Christopher D. Thanos | M | - |
Actym Therapeutics, Inc.
![]() Actym Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actym Therapeutics, Inc. engages in development of novel immuno-oncology therapies. The company was founded by Christopher D. Thanos and Laura Hix Glickman and is headquartered in Berkeley, CA. | 7 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 14 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Thomas Smart
- Persönliches Netzwerk